Peijia Medical, a global provider of innovative medical solutions, recently held an Open Day event at its global headquarters in SIP, attracting over 150 investors and analysts. The event showcased the company’s rapid growth and strength.
With eye-catching growth in both transcatheter aortic valve replacement (TAVR) and neurointerventional devices, Peijia Medical has achieved an over 25% share in the domestic TAVR devices market in the first quarter of this year (up from less than 5% in 2021), while its neurointerventional products division turned profitable last year with income surging 39.1% year-on-year to RMB356 million.
The products under research became the focus of the Open Day. Among them are three much-anticipated products: the TaurusTrioTM TAVR system, the TaurusNXT ? TAVR system, and the ReachTactile, a robot-assisted TAVR system. These products are expected to alter the landscape of TAVR and benefit numerous patients.
From local R&D to global expansion, the company is redefining minimally invasive therapies. According to its CEO Zhang Yi, in addition to striving to extend its products’ service life and enhance their technological sophistication, the company is enhancing efforts to explore overseas markets.
July 25, 2025
